BNY Mellon International Equity ETF
BKIE
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management - Global
- Address
- 240 Greenwich Street New York NY United States of America 10286
- IPO Date
- Apr 24, 2020
- CIK
- 0001493580
- Website
- im.bnymellon.com
- Similar Companies
- Business
- BNY Mellon International Equity ETF (BKIE) is a passively managed exchange-traded fund that seeks to match the performance of the Solactive GBS Developed Markets ex United States Large & Mid Cap Index NTR, providing investors with broad exposure to large- and mid-cap equities in developed markets outside the United States. The ETF holds approximately 1,011 securities, with top holdings including ASML Holding NV, Roche Holding AG, AstraZeneca PLC, HSBC Holdings PLC, and Novartis AG; it employs a low-cost index-tracking approach featuring a fully transparent portfolio, high liquidity, and an expense ratio of 0.04%. BKIE trades on NYSE Arca under the ticker BKIE with CUSIP 09661T404 and is managed by a team at Mellon Investments Corporation, including portfolio managers David France, Todd Frysinger, Vlasta Sheremeta, Michael Stoll, and Marlene Walker-Smith. Launched on April 22, 2020, BKIE is issued by BNY Mellon ETF Trust and headquartered in New York, New York, as part of BNY Mellon Investment Management's suite of ETFs focused on international equity strategies. The fund targets institutional and retail investors seeking diversified access to foreign large-blend equities across sectors such as financials, industrials, health care, and consumer staples; its geographic footprint spans developed markets in Europe (e.g., Switzerland, United Kingdom, Germany, France), Asia-Pacific (e.g., Japan, Australia, Canada), and other regions excluding the U.S. and emerging markets. Recent developments include sustained asset growth to over $1 billion in assets under management as of late 2025, reflecting strong inflows amid favorable international market performance; the fund delivered a year-to-date NAV total return of approximately 30% as of December 16, 2025, and earned a 4-Star Morningstar rating in the Foreign Large Blend category. In July 2025, BNY Mellon expanded its ETF servicing partnership with Franklin Templeton to provide full lifecycle support via its Exchange Traded Execution platform, enhancing operational efficiency for third-party ETF issuers though not directly impacting BKIE operations. The benchmark index transitioned from the Morningstar Developed Markets ex-US Large Cap Index to the current Solactive index, maintaining the fund's core strategy without altering its passive replication methodology.